CN Patent

CN110799191B — N-(2-(2-(二甲氨基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)氨基)苯基)丙烯酰胺及其盐的药物制剂

Assigned to Zhejiang Beta Pharma Inc · Expires 2023-05-26 · 3y expired

What this patent protects

公开了一种N‑(2‑(2‑(二甲氨基)乙氧基)‑4‑甲氧基‑5‑((4‑(1‑甲基‑1H‑吲哚‑3‑基)嘧啶‑2‑基)氨基)苯基)丙烯酰胺(化合物1)、特别是其甲磺酸盐的药物制剂，并且公开了使用所述药物制剂治疗或预防通过表皮生长因子受体(EGFR)的突变形式介导的疾病或医学病症例如各种癌症的方法。

USPTO Abstract

公开了一种N‑(2‑(2‑(二甲氨基)乙氧基)‑4‑甲氧基‑5‑((4‑(1‑甲基‑1H‑吲哚‑3‑基)嘧啶‑2‑基)氨基)苯基)丙烯酰胺(化合物1)、特别是其甲磺酸盐的药物制剂，并且公开了使用所述药物制剂治疗或预防通过表皮生长因子受体(EGFR)的突变形式介导的疾病或医学病症例如各种癌症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN110799191B
Jurisdiction
CN
Classification
—
Expires
2023-05-26
Drug substance claim
No
Drug product claim
No
Assignee
Zhejiang Beta Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.